Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

8,848 13,470 15,789 25,345 152,987 General and administrative 5,118 5,223 10,305 10,419 68,154 Impairment of leasehold improvements - - - - 1,030 Depreciation and amortization 332 519 653 1,024 5,311 In-process research and development - - - - 418 Total operating expenses 14,298 19,212 26,747 36,788 227,900 Loss from operations (10,491) (13,851) (19,779) (26,819) (201,181) Other income (expenses): Interest income 1,331 269 3,034 795 13,555 Interest expense (59) (41) (129) (71) (1,718) Change in fair value of warrant liability - - - - (454) Other expense - - - - (1,180) Loss before tax benefit (9,219) (13,623) (16,874) (26,095) (190,978) (Provision for)/ benefit from income taxes (75) - (150) - 695 Net loss (9,294) (13,623) (17,024) (26,095) (190,283) Deemed dividend - - - - (19,424) Preferred stock accretion - - - - (802) Net loss attributable to common stockholders $(9,294) $(13,623) $(17,024) $(26,095)$(210,509) Net loss attributable to common stockholders per common share - basic and diluted $(0.41) $(0.60) $(0.76) $(1.15) Weighted-average common shares outstanding - basic and diluted 22,467,198 22,618,026 22,439,893 22,615,951


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ) ... President and Chief Executive Officer, will present at the ... on Wednesday, May 13, 2015 at 4:20 p.m. ET. ... can be accessed at AMRI,s Investor Relations web site at ... be archived for 90 days following the live presentation. ...
(Date:4/30/2015)... 01, 2015 Spirax Sarco, the leader ... proud to announce that for the first time in ... winner of a Queen’s Award for Innovation – the ... and manufacture of a unique flowmeter. , The Spirax ... to traditional steam flow measurement. The device provides ...
(Date:4/30/2015)... April 30, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... of 2015 were $4.4 million, compared to $8.0 million during ... the first quarter was $8.9 million, or $0.23 per basic ... for the same period in 2014, of $8.7 million, or ... 31, 2015, cash, cash equivalents and investments totaled $117.5 million. ...
(Date:4/30/2015)... ALEXANDRIA, Va. , April 30, 2015 ... provides senior debt to life sciences and healthcare services ... senior secured term loan agreement with Celula, Inc., a ... diagnosing major diseases, enabling better patient care and improved ... continue the development and expand the commercialization of its ...
Breaking Biology Technology:AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Oxford Finance Provides $10 Million Debt Financing to Celula 2
... -- ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") ... a new patent that provides broad protection on novel ... the "Zamore Design Rules."  European patent number 1 633 ... and Specificity of RNAi" was published today in the ...
Cached Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 2China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 4China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 5China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 6China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 7China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 8JIPH Accepted for MEDLINE Indexing 2JIPH Accepted for MEDLINE Indexing 3JIPH Accepted for MEDLINE Indexing 4JIPH Accepted for MEDLINE Indexing 5JIPH Accepted for MEDLINE Indexing 6JIPH Accepted for MEDLINE Indexing 7JIPH Accepted for MEDLINE Indexing 8JIPH Accepted for MEDLINE Indexing 9Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent 2Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent 3
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... conducting a detailed study of the potential environmental and ... drilling process known as fracking. In hydraulic fracturing, ... deep underground to break apart rock and free trapped ... decades, recent technical advances have helped unlock vast stores ...
... pound, spider silk is one of the strongest materials known: ... strength arises from silk,s unusual hierarchical arrangement of protein building ... Tufts University and Joyce Wong of Boston University has ... method for making further improvements in the synthetic material. ...
... Shenzhen and Hong Kong, China BGI, the ... advances in the analysis, management and dissemination of ... and data release conference. Released at the conference ... SOAPhecate v2.5 and SOAPgaea, as well as an ...
Cached Biology News:Fracking in Michigan: U-M researchers study potential impact on health, environment, economy 2Fracking in Michigan: U-M researchers study potential impact on health, environment, economy 3Fracking in Michigan: U-M researchers study potential impact on health, environment, economy 4The music of the silks 2The music of the silks 3Big genomics data, big scientific impact: New challenges for further development of life science 2Big genomics data, big scientific impact: New challenges for further development of life science 3Big genomics data, big scientific impact: New challenges for further development of life science 4
... Cy5 Post-Labeling Reactive Dye Pack, ... CyDye fluors specifically optimized for microarray ... 40000 pmol reactive dye per vial, ... to use, individually dispensed, and packed ...
... with CyScribe GFX Purification Kit, 24 ... of Cy3- and Cy5-labeled cDNA.Optimized reagents ... labeling and purification.Flexible and optimized protocols ... reactions with either Cy3- or Cy5-labeled ...
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
NORMAL DONOR DONKEY SERUM...
Biology Products: